← Eichor
Condition: Her2 Low Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Her2 Low Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06176534Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06254690Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and C
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06298084Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvan
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06389006A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER
NA · 1 location(s) · QIAO LI · NCT07117864HER2-PET Imaging in HER2-low Breast Cancers
Phase 1/Phase 2 · 1 location(s) · Centre de recherche du Centre hospitalier universitaire de S · NCT06732336SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
Phase 2 · 1 location(s) · Shengjing Hospital · NCT06340230Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Phase 3 · 3 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05904964Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other
Phase 1 · 7 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05461768Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negati
Phase 2 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT07276880PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · 71 location(s) · West German Study Group · NCT05792150Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
Phase N/A · 1 location(s) · Shu Wang · NCT06722599Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Phase 2 · 3 location(s) · Reshma L. Mahtani, D.O. · NCT06263543Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
NA · 1 location(s) · University of Rochester · NCT07630402Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic
Phase 3 · 72 location(s) · National Cancer Institute (NCI) · NCT07391774Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced
Phase 4 · 11 location(s) · Institut Claudius Regaud · NCT07195344A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Phase N/A · 54 location(s) · Daiichi Sankyo · NCT06210776IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stag
Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT06797635A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Adva
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06832202
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.